AzTrials
AzTrials

Atrial FibrillationPhase 3NCT00808067

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

A Phase 3 study testing dabigatran dose 1 and dabigatran dose 2 in people with Atrial Fibrillation, run by Boehringer Ingelheim at 567 sites in 35 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrial Fibrillation
What is being tested?
dabigatran dose 1 and dabigatran dose 2
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5,897 participants
Where
567 sitesin 35 countries
Study dates
Nov 2008to Dec 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participation in RE-LY, requires long term anticoagulation, provides written informed consent

Who cannot join

  • Permanent discontinuation of dabigatran during RE-LY

Trial locations and contacts

567 sites in 35 countries.

567 sites in 35 countries

United States216 sites

  • 1160.71.0203 Boehringer Ingelheim Investigational Site

    Akron, Ohio

  • 1160.71.0476 Boehringer Ingelheim Investigational Site

    Albany, New York

  • 1160.71.0301 Boehringer Ingelheim Investigational Site

    Allentown, Pennsylvania

  • 1160.71.0114 Boehringer Ingelheim Investigational Site

    Annapolis, Maryland

  • 1160.71.0353 Boehringer Ingelheim Investigational Site

    Asheville, North Carolina

  • 1160.71.0159 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1160.71.0096 Boehringer Ingelheim Investigational Site

    Auburn, Maine

  • 1160.71.0021 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 1160.71.0129 Boehringer Ingelheim Investigational Site

    Austin, Texas

  • 1160.71.0410 Boehringer Ingelheim Investigational Site

    Austin, Texas

  • 1160.71.0023 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1160.71.0047 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1160.71.0079 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1160.71.0186 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1160.71.0194 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1160.71.0144 Boehringer Ingelheim Investigational Site

    Baton Rouge, Louisiana

  • 1160.71.0007 Boehringer Ingelheim Investigational Site

    Beaufort, South Carolina

  • 1160.71.0255 Boehringer Ingelheim Investigational Site

    Bel Air, Maryland

  • 1160.71.0050 Boehringer Ingelheim Investigational Site

    Bellingham, Washington

  • 1160.71.0046 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0057 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0211 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0382 Boehringer Ingelheim Investigational Site

    Boynton Beach, Florida

  • 1160.71.0056 Boehringer Ingelheim Investigational Site

    Brandon, Florida

  • 1160.71.0278 Boehringer Ingelheim Investigational Site

    Bridgeport, Connecticut

  • 1160.71.0142 Boehringer Ingelheim Investigational Site

    Browns Mills, New Jersey

  • 1160.71.0040 Boehringer Ingelheim Investigational Site

    Burien, Washington

  • 1160.71.0295 Boehringer Ingelheim Investigational Site

    Camp Hill, Pennsylvania

  • 1160.71.0434 Boehringer Ingelheim Investigational Site

    Canal Fulton, Ohio

  • 1160.71.0441 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 1160.71.0383 Boehringer Ingelheim Investigational Site

    Charleston, South Carolina

  • 1160.71.0080 Boehringer Ingelheim Investigational Site

    Charlotte, North Carolina

  • 1160.71.0453 Boehringer Ingelheim Investigational Site

    Charlottesville, Virginia

  • 1160.71.0084 Boehringer Ingelheim Investigational Site

    Chattanooga, Tennessee

  • 1160.71.0221 Boehringer Ingelheim Investigational Site

    Cherry Hill, New Jersey

  • 1160.71.0053 Boehringer Ingelheim Investigational Site

    Chesapeake, Virginia

  • 1160.71.0218 Boehringer Ingelheim Investigational Site

    Cicero, Illinois

  • 1160.71.0402 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1160.71.0426 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1160.71.0479 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1160.71.0169 Boehringer Ingelheim Investigational Site

    Clarksburg, West Virginia

  • 1160.71.0296 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1160.71.0263 Boehringer Ingelheim Investigational Site

    Cleveland, Ohio

  • 1160.71.0480 Boehringer Ingelheim Investigational Site

    Cleveland, Ohio

  • 1160.71.0474 Boehringer Ingelheim Investigational Site

    Clinton, Tennessee

  • 1160.71.0321 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1160.71.0449 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1160.71.0398 Boehringer Ingelheim Investigational Site

    Columbia, Maryland

  • 1160.71.0055 Boehringer Ingelheim Investigational Site

    Columbia, Missouri

  • 1160.71.0267 Boehringer Ingelheim Investigational Site

    Columbus, Ohio

  • 1160.71.0161 Boehringer Ingelheim Investigational Site

    Conyers, Georgia

  • 1160.71.0327 Boehringer Ingelheim Investigational Site

    Coral Springs, Florida

  • 1160.71.0044 Boehringer Ingelheim Investigational Site

    Cortlandt Manor, New York

  • 1160.71.0139 Boehringer Ingelheim Investigational Site

    Corvallis, Oregon

  • 1160.71.0156 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 1160.71.0035 Boehringer Ingelheim Investigational Site

    Dayton, Ohio

  • 1160.71.0376 Boehringer Ingelheim Investigational Site

    Daytona Beach, Florida

  • 1160.71.0360 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1160.71.0413 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1160.71.0268 Boehringer Ingelheim Investigational Site

    Dubuque, Iowa

  • 1160.71.0325 Boehringer Ingelheim Investigational Site

    Eugene, Oregon

  • 1160.71.0150 Boehringer Ingelheim Investigational Site

    Fairview Park, Ohio

  • 1160.71.0248 Boehringer Ingelheim Investigational Site

    Flemington, New Jersey

  • 1160.71.0362 Boehringer Ingelheim Investigational Site

    Fort Collins, Colorado

  • 1160.71.0074 Boehringer Ingelheim Investigational Site

    Fort Myers, Florida

  • 1160.71.0377 Boehringer Ingelheim Investigational Site

    Fort Wayne, Indiana

  • 1160.71.0315 Boehringer Ingelheim Investigational Site

    Fort Worth, Texas

  • 1160.71.0428 Boehringer Ingelheim Investigational Site

    Fredericksburg, Virginia

  • 1160.71.0333 Boehringer Ingelheim Investigational Site

    Fullerton, California

  • 1160.71.0350 Boehringer Ingelheim Investigational Site

    Gastonia, North Carolina

  • 1160.71.0062 Boehringer Ingelheim Investigational Site

    Germantown, Tennessee

  • 1160.71.0154 Boehringer Ingelheim Investigational Site

    Grand Blanc, Michigan

  • 1160.71.0102 Boehringer Ingelheim Investigational Site

    Grand Forks, North Dakota

  • 1160.71.0313 Boehringer Ingelheim Investigational Site

    Greenville, South Carolina

  • 1160.71.0482 Boehringer Ingelheim Investigational Site

    Guilford, Connecticut

  • 1160.71.0086 Boehringer Ingelheim Investigational Site

    Gulfport, Mississippi

  • 1160.71.0311 Boehringer Ingelheim Investigational Site

    Harrisonburg, Virginia

  • 1160.71.0443 Boehringer Ingelheim Investigational Site

    Haverhill, Massachusetts

  • 1160.71.0452 Boehringer Ingelheim Investigational Site

    Haverhill, Massachusetts

  • 1160.71.0346 Boehringer Ingelheim Investigational Site

    Henderson, Nevada

  • 1160.71.0294 Boehringer Ingelheim Investigational Site

    Hershey, Pennsylvania

  • 1160.71.0173 Boehringer Ingelheim Investigational Site

    High Point, North Carolina

  • 1160.71.0038 Boehringer Ingelheim Investigational Site

    Hot Springs, Arkansas

  • 1160.71.0447 Boehringer Ingelheim Investigational Site

    Houston, Texas

  • 1160.71.0365 Boehringer Ingelheim Investigational Site

    Huntington, West Virginia

  • 1160.71.0288 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 1160.71.0352 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 1160.71.0436 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 1160.71.0089 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0232 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0427 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0222 Boehringer Ingelheim Investigational Site

    Jamestown, North Dakota

  • 1160.71.0369 Boehringer Ingelheim Investigational Site

    Jenkintown, Pennsylvania

  • 1160.71.0370 Boehringer Ingelheim Investigational Site

    Johnson City, Tennessee

  • 1160.71.0302 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 1160.71.0027 Boehringer Ingelheim Investigational Site

    Kalispell, Montana

  • 1160.71.0257 Boehringer Ingelheim Investigational Site

    Kansas City, Missouri

  • 1160.71.0201 Boehringer Ingelheim Investigational Site

    Kettering, Ohio

  • 1160.71.0483 Boehringer Ingelheim Investigational Site

    Killeen, Texas

  • 1160.71.0384 Boehringer Ingelheim Investigational Site

    La Jolla, California

  • 1160.71.0018 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 1160.71.0104 Boehringer Ingelheim Investigational Site

    Lake Havasu City, Arizona

  • 1160.71.0012 Boehringer Ingelheim Investigational Site

    Lakeland, Florida

  • 1160.71.0246 Boehringer Ingelheim Investigational Site

    Lancaster, California

  • 1160.71.0431 Boehringer Ingelheim Investigational Site

    Lancaster, Pennsylvania

  • 1160.71.0168 Boehringer Ingelheim Investigational Site

    Langhorne, Pennsylvania

  • 1160.71.0205 Boehringer Ingelheim Investigational Site

    Lapeer, Michigan

  • 1160.71.0430 Boehringer Ingelheim Investigational Site

    Las Vegas, Nevada

  • 1160.71.0422 Boehringer Ingelheim Investigational Site

    Lexington, Kentucky

  • 1160.71.0191 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.71.0213 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.71.0223 Boehringer Ingelheim Investigational Site

    Lorain, Ohio

  • 1160.71.0178 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1160.71.0397 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1160.71.0335 Boehringer Ingelheim Investigational Site

    Lubbock, Texas

  • 1160.71.0214 Boehringer Ingelheim Investigational Site

    Lyndhurst, Ohio

  • 1160.71.0099 Boehringer Ingelheim Investigational Site

    Madison, Wisconsin

  • 1160.71.0438 Boehringer Ingelheim Investigational Site

    Maywood, Illinois

  • 1160.71.0293 Boehringer Ingelheim Investigational Site

    Meadowbrook, Pennsylvania

  • 1160.71.0331 Boehringer Ingelheim Investigational Site

    Melrose Park, Illinois

  • 1160.71.0070 Boehringer Ingelheim Investigational Site

    Merced, California

  • 1160.71.0034 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1160.71.0072 Boehringer Ingelheim Investigational Site

    Milwaukee, Wisconsin

  • 1160.71.0461 Boehringer Ingelheim Investigational Site

    Milwaukee, Wisconsin

  • 1160.71.0229 Boehringer Ingelheim Investigational Site

    Mineola, New York

  • 1160.71.0451 Boehringer Ingelheim Investigational Site

    Mineola, New York

  • 1160.71.0202 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

  • 1160.71.0115 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1160.71.0279 Boehringer Ingelheim Investigational Site

    Muskegon, Michigan

  • 1160.71.0395 Boehringer Ingelheim Investigational Site

    Nashville, Tennessee

  • 1160.71.0029 Boehringer Ingelheim Investigational Site

    Natick, Massachusetts

  • 1160.71.0132 Boehringer Ingelheim Investigational Site

    New Iberia, Louisiana

  • 1160.71.0183 Boehringer Ingelheim Investigational Site

    New Rochelle, New York

  • 1160.71.0292 Boehringer Ingelheim Investigational Site

    Newport News, Virginia

  • 1160.71.0364 Boehringer Ingelheim Investigational Site

    Normal, Illinois

  • 1160.71.0394 Boehringer Ingelheim Investigational Site

    Norristown, Pennsylvania

  • 1160.71.0109 Boehringer Ingelheim Investigational Site

    North Chicago, Illinois

  • 1160.71.0003 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 1160.71.0210 Boehringer Ingelheim Investigational Site

    Northport, New York

  • 1160.71.0152 Boehringer Ingelheim Investigational Site

    Oak Lawn, Illinois

  • 1160.71.0349 Boehringer Ingelheim Investigational Site

    Oakland, California

  • 1160.71.0478 Boehringer Ingelheim Investigational Site

    Oakland, New Jersey

  • 1160.71.0392 Boehringer Ingelheim Investigational Site

    Ocean City, New Jersey

  • 1160.71.0016 Boehringer Ingelheim Investigational Site

    Oceanside, California

  • 1160.71.0110 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1160.71.0227 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1160.71.0095 Boehringer Ingelheim Investigational Site

    Ormond Beach, Florida

  • 1160.71.0310 Boehringer Ingelheim Investigational Site

    Owensboro, Kentucky

  • 1160.71.0459 Boehringer Ingelheim Investigational Site

    Pasadena, California

  • 1160.71.0037 Boehringer Ingelheim Investigational Site

    Pensacola, Florida

  • 1160.71.0445 Boehringer Ingelheim Investigational Site

    Petoskey, Michigan

  • 1160.71.0006 Boehringer Ingelheim Investigational Site

    Pinehurst, North Carolina

  • 1160.71.0466 Boehringer Ingelheim Investigational Site

    Pittsburgh, Pennsylvania

  • 1160.71.0137 Boehringer Ingelheim Investigational Site

    Port Charlotte, Florida

  • 1160.71.0417 Boehringer Ingelheim Investigational Site

    Port Charlotte, Florida

  • 1160.71.0075 Boehringer Ingelheim Investigational Site

    Poughkeepsie, New York

  • 1160.71.0270 Boehringer Ingelheim Investigational Site

    Poway, California

  • 1160.71.0135 Boehringer Ingelheim Investigational Site

    Riverside, California

  • 1160.71.0274 Boehringer Ingelheim Investigational Site

    Rochester Hills, Michigan

  • 1160.71.0198 Boehringer Ingelheim Investigational Site

    Rockford, Illinois

  • 1160.71.0332 Boehringer Ingelheim Investigational Site

    Rockledge, Florida

  • 1160.71.0177 Boehringer Ingelheim Investigational Site

    Rockville, Maryland

  • 1160.71.0300 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 1160.71.0165 Boehringer Ingelheim Investigational Site

    Saginaw, Michigan

  • 1160.71.0336 Boehringer Ingelheim Investigational Site

    Saint Charles, Missouri

  • 1160.71.0101 Boehringer Ingelheim Investigational Site

    Saint Paul, Minnesota

  • 1160.71.0220 Boehringer Ingelheim Investigational Site

    Salem, Virginia

  • 1160.71.0073 Boehringer Ingelheim Investigational Site

    Salisbury, Maryland

  • 1160.71.0207 Boehringer Ingelheim Investigational Site

    Salisbury, Maryland

  • 1160.71.0269 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1160.71.0307 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1160.71.0284 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1160.71.0285 Boehringer Ingelheim Investigational Site

    San Marcos, Texas

  • 1160.71.0275 Boehringer Ingelheim Investigational Site

    Sandusky, Ohio

  • 1160.71.0385 Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • 1160.71.0208 Boehringer Ingelheim Investigational Site

    Sellersville, Pennsylvania

  • 1160.71.0235 Boehringer Ingelheim Investigational Site

    South Bend, Indiana

  • 1160.71.0166 Boehringer Ingelheim Investigational Site

    Spartanburg, South Carolina

  • 1160.71.0250 Boehringer Ingelheim Investigational Site

    Spokane, Washington

  • 1160.71.0133 Boehringer Ingelheim Investigational Site

    Springfield, Oregon

  • 1160.71.0249 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 1160.71.0015 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1160.71.0339 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1160.71.0002 Boehringer Ingelheim Investigational Site

    Statesville, North Carolina

  • 1160.71.0069 Boehringer Ingelheim Investigational Site

    Statesville, North Carolina

  • 1160.71.0224 Boehringer Ingelheim Investigational Site

    Suffolk, Virginia

  • 1160.71.0008 Boehringer Ingelheim Investigational Site

    Summerville, South Carolina

  • 1160.71.0256 Boehringer Ingelheim Investigational Site

    Tacoma, Washington

  • 1160.71.0196 Boehringer Ingelheim Investigational Site

    Takoma Park, Maryland

  • 1160.71.0113 Boehringer Ingelheim Investigational Site

    The Bronx, New York

  • 1160.71.0281 Boehringer Ingelheim Investigational Site

    The Bronx, New York

  • 1160.71.0187 Boehringer Ingelheim Investigational Site

    Towson, Maryland

  • 1160.71.0020 Boehringer Ingelheim Investigational Site

    Troy, Michigan

  • 1160.71.0414 Boehringer Ingelheim Investigational Site

    Troy, New York

  • 1160.71.0185 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 1160.71.0435 Boehringer Ingelheim Investigational Site

    Tulsa, Oklahoma

  • 1160.71.0119 Boehringer Ingelheim Investigational Site

    Tupelo, Mississippi

  • 1160.71.0367 Boehringer Ingelheim Investigational Site

    Tyler, Texas

  • 1160.71.0465 Boehringer Ingelheim Investigational Site

    Uniontown, Pennsylvania

  • 1160.71.0019 Boehringer Ingelheim Investigational Site

    Vero Beach, Florida

  • 1160.71.0379 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 1160.71.0356 Boehringer Ingelheim Investigational Site

    Watertown, New York

  • 1160.71.0024 Boehringer Ingelheim Investigational Site

    Wenatchee, Washington

  • 1160.71.0001 Boehringer Ingelheim Investigational Site

    West Des Moines, Iowa

  • 1160.71.0357 Boehringer Ingelheim Investigational Site

    West Des Moines, Iowa

  • 1160.71.0103 Boehringer Ingelheim Investigational Site

    Westlake, Ohio

  • 1160.71.0052 Boehringer Ingelheim Investigational Site

    Westminster, Maryland

  • 1160.71.0254 Boehringer Ingelheim Investigational Site

    Westwood, New Jersey

  • 1160.71.0317 Boehringer Ingelheim Investigational Site

    Winchester, Virginia

  • 1160.71.0433 Boehringer Ingelheim Investigational Site

    Winfield, Illinois

  • 1160.71.0472 Boehringer Ingelheim Investigational Site

    Woodland Park, New Jersey

  • 1160.71.0308 Boehringer Ingelheim Investigational Site

    Worcester, Massachusetts

  • 1160.71.0032 Boehringer Ingelheim Investigational Site

    Wynnewood, Pennsylvania

  • 1160.71.0067 Boehringer Ingelheim Investigational Site

    Wyomissing, Pennsylvania

  • 1160.71.0064 Boehringer Ingelheim Investigational Site

    Yonkers, New York

  • 1160.71.0188 Boehringer Ingelheim Investigational Site

    Ypsilanti, Michigan

Other trials in United States

Canada40 sites

  • 1160.71.0674 Boehringer Ingelheim Investigational Site

    Burlington, Ontario

  • 1160.71.0694 Boehringer Ingelheim Investigational Site

    Calgary, Alberta

  • 1160.71.0696 Boehringer Ingelheim Investigational Site

    Calgary, Alberta

  • 1160.71.0702 Boehringer Ingelheim Investigational Site

    Cambridge, Ontario

  • 1160.71.0720 Boehringer Ingelheim Investigational Site

    Cambridge, Ontario

  • 1160.71.0680 Boehringer Ingelheim Investigational Site

    Coquitlam, British Columbia

  • 1160.71.0712 Boehringer Ingelheim Investigational Site

    Coquitlam, British Columbia

  • 1160.71.0715 Boehringer Ingelheim Investigational Site

    Greater Sudbury, Ontario

  • 1160.71.0692 Boehringer Ingelheim Investigational Site

    Grimsby, Ontario

  • 1160.71.0703 Boehringer Ingelheim Investigational Site

    Halifax, Nova Scotia

  • 1160.71.0697 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario

  • 1160.71.0710 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario

  • 1160.71.0719 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario

  • 1160.71.0721 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario

  • 1160.71.0706 Boehringer Ingelheim Investigational Site

    Kelowna, British Columbia

  • 1160.71.0708 Boehringer Ingelheim Investigational Site

    Mississauga, Ontario

  • 1160.71.0683 Boehringer Ingelheim Investigational Site

    Montreal, Quebec

  • 1160.71.0705 Boehringer Ingelheim Investigational Site

    Montreal, Quebec

  • 1160.71.0709 Boehringer Ingelheim Investigational Site

    Montreal, Quebec

  • 1160.71.0716 Boehringer Ingelheim Investigational Site

    Montreal, Quebec

  • 1160.71.0725 Boehringer Ingelheim Investigational Site

    Nanaimo, British Columbia

  • 1160.71.0691 Boehringer Ingelheim Investigational Site

    New Westminster, British Columbia

  • 1160.71.0688 Boehringer Ingelheim Investigational Site

    Newmarket, Ontario

  • 1160.71.0672 Boehringer Ingelheim Investigational Site

    Oshawa, Ontario

  • 1160.71.0687 Boehringer Ingelheim Investigational Site

    Ottawa, Ontario

  • 1160.71.0701 Boehringer Ingelheim Investigational Site

    Portage la Prairie, Manitoba

  • 1160.71.0700 Boehringer Ingelheim Investigational Site

    Québec, Quebec

  • 1160.71.0717 Boehringer Ingelheim Investigational Site

    Québec, Quebec

  • 1160.71.0713 Boehringer Ingelheim Investigational Site

    Saint George-de-Beauce, Quebec

  • 1160.71.0699 Boehringer Ingelheim Investigational Site

    Saint-Charles-Borromée, Quebec

  • 1160.71.0675 Boehringer Ingelheim Investigational Site

    Saint-Hyacinthe, Quebec

  • 1160.71.0673 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan

  • 1160.71.0678 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan

  • 1160.71.0679 Boehringer Ingelheim Investigational Site

    Scarborough Village, Ontario

  • 1160.71.0723 Boehringer Ingelheim Investigational Site

    Scarborough Village, Ontario

  • 1160.71.0690 Boehringer Ingelheim Investigational Site

    Thunder Bay, Ontario

  • 1160.71.0684 Boehringer Ingelheim Investigational Site

    Toronto, Ontario

  • 1160.71.0718 Boehringer Ingelheim Investigational Site

    Toronto, Ontario

  • 1160.71.0714 Boehringer Ingelheim Investigational Site

    Victoria, British Columbia

  • 1160.71.0686 Boehringer Ingelheim Investigational Site

    Windsor, Ontario

Other trials in Canada

Netherlands27 sites

  • 1160.71.1337 Boehringer Ingelheim Investigational Site

    's-Hertogenbosch

  • 1160.71.1344 Boehringer Ingelheim Investigational Site

    Almelo

  • 1160.71.1331 Boehringer Ingelheim Investigational Site

    Amsterdam

  • 1160.71.1336 Boehringer Ingelheim Investigational Site

    Apeldoorn

  • 1160.71.1332 Boehringer Ingelheim Investigational Site

    Breda

  • 1160.71.1349 Boehringer Ingelheim Investigational Site

    Den Helder

  • 1160.71.1345 Boehringer Ingelheim Investigational Site

    Deventer

  • 1160.71.1360 Boehringer Ingelheim Investigational Site

    Dirksland

  • 1160.71.1340 Boehringer Ingelheim Investigational Site

    Ede

  • 1160.71.1358 Boehringer Ingelheim Investigational Site

    Eindhoven

  • 1160.71.1338 Boehringer Ingelheim Investigational Site

    Enschede

  • 1160.71.1343 Boehringer Ingelheim Investigational Site

    Goes

  • 1160.71.1347 Boehringer Ingelheim Investigational Site

    Gorinchem

  • 1160.71.1333 Boehringer Ingelheim Investigational Site

    Groningen

  • 1160.71.1361 Boehringer Ingelheim Investigational Site

    Heerlen

  • 1160.71.1339 Boehringer Ingelheim Investigational Site

    Hengelo

  • 1160.71.1346 Boehringer Ingelheim Investigational Site

    Hilversum

  • 1160.71.1356 Boehringer Ingelheim Investigational Site

    Hoorn

  • 1160.71.1359 Boehringer Ingelheim Investigational Site

    Maastricht

  • 1160.71.1341 Boehringer Ingelheim Investigational Site

    Meppel

  • 1160.71.1354 Boehringer Ingelheim Investigational Site

    Rotterdam

  • 1160.71.1351 Boehringer Ingelheim Investigational Site

    Sneek

  • 1160.71.1353 Boehringer Ingelheim Investigational Site

    Tiel

  • 1160.71.1352 Boehringer Ingelheim Investigational Site

    Tilburg

  • 1160.71.1350 Boehringer Ingelheim Investigational Site

    Veldhoven

  • 1160.71.1342 Boehringer Ingelheim Investigational Site

    Velp

  • 1160.71.1348 Boehringer Ingelheim Investigational Site

    Zwijndrecht

Other trials in Netherlands

France26 sites

  • 1160.71.875A Boehringer Ingelheim Investigational Site

    Abbeville

  • 1160.71.882D Boehringer Ingelheim Investigational Site

    Angers

  • 1160.71.882G Boehringer Ingelheim Investigational Site

    Angers

  • 1160.71.879F Boehringer Ingelheim Investigational Site

    Besle Sur Vilaine

  • 1160.71.882K Boehringer Ingelheim Investigational Site

    Château-Gontier

  • 1160.71.887A Boehringer Ingelheim Investigational Site

    Cholet

  • 1160.71.879C Boehringer Ingelheim Investigational Site

    Derval

  • 1160.71.882H Boehringer Ingelheim Investigational Site

    Feneu

  • 1160.71.888A Boehringer Ingelheim Investigational Site

    Grenoble Cédex 9

  • 1160.71.879B Boehringer Ingelheim Investigational Site

    La Chapelle-sur-Erdre

  • 1160.71.874A Boehringer Ingelheim Investigational Site

    Langres

  • 1160.71.884A Boehringer Ingelheim Investigational Site

    Laval

  • 1160.71.880B Boehringer Ingelheim Investigational Site

    Le Mesnil En Valée

  • 1160.71.880A Boehringer Ingelheim Investigational Site

    Mûrs-Erigné

  • 1160.71.879A Boehringer Ingelheim Investigational Site

    Nantes

  • 1160.71.879H Boehringer Ingelheim Investigational Site

    Nantes

  • 1160.71.879S Boehringer Ingelheim Investigational Site

    Nantes

  • 1160.71.880J Boehringer Ingelheim Investigational Site

    Parçay-les-Pins

  • 1160.71.871A Boehringer Ingelheim Investigational Site

    Paris

  • 1160.71.879E Boehringer Ingelheim Investigational Site

    Saint-Aubin-des-Châteaux

  • 1160.71.880D Boehringer Ingelheim Investigational Site

    Segré

  • 1160.71.882A Boehringer Ingelheim Investigational Site

    Tiercé

  • 1160.71.882B Boehringer Ingelheim Investigational Site

    Tiercé

  • 1160.71.882C Boehringer Ingelheim Investigational Site

    Tiercé

  • 1160.71.879G Boehringer Ingelheim Investigational Site

    Vieillevigne

  • 1160.71.880E Boehringer Ingelheim Investigational Site

    Vihiers

Other trials in France

Israel26 sites

  • 1160.71.1110 Boehringer Ingelheim Investigational Site

    Afula

  • 1160.71.1121 Boehringer Ingelheim Investigational Site

    Afula

  • 1160.71.1111 Boehringer Ingelheim Investigational Site

    Ashkelon

  • 1160.71.1117 Boehringer Ingelheim Investigational Site

    Giv‘atayim

  • 1160.71.1112 Boehringer Ingelheim Investigational Site

    Hadera

  • 1160.71.1091 Boehringer Ingelheim Investigational Site

    Haifa

  • 1160.71.1113 Boehringer Ingelheim Investigational Site

    Haifa

  • 1160.71.1114 Boehringer Ingelheim Investigational Site

    Haifa

  • 1160.71.1116 Boehringer Ingelheim Investigational Site

    Haifa

  • 1160.71.1118 Boehringer Ingelheim Investigational Site

    Haifa

  • 1160.71.1105 Boehringer Ingelheim Investigational Site

    Holon

  • 1160.71.1101 Boehringer Ingelheim Investigational Site

    Jerusalem

  • 1160.71.1104 Boehringer Ingelheim Investigational Site

    Jerusalem

  • 1160.71.1106 Boehringer Ingelheim Investigational Site

    Jerusalem

  • 1160.71.1119 Boehringer Ingelheim Investigational Site

    Kfar Saba

  • 1160.71.1096 Boehringer Ingelheim Investigational Site

    Petah Tikva

  • 1160.71.1093 Boehringer Ingelheim Investigational Site

    Ramat Gan

  • 1160.71.1094 Boehringer Ingelheim Investigational Site

    Ramat Gan

  • 1160.71.1095 Boehringer Ingelheim Investigational Site

    Ramat Gan

  • 1160.71.1100 Boehringer Ingelheim Investigational Site

    Rehovot

  • 1160.71.1103 Boehringer Ingelheim Investigational Site

    Safed

  • 1160.71.1107 Boehringer Ingelheim Investigational Site

    Tel Aviv

  • 1160.71.1108 Boehringer Ingelheim Investigational Site

    Tel Aviv

  • 1160.71.1109 Boehringer Ingelheim Investigational Site

    Tel Aviv

  • 1160.71.1120 Boehringer Ingelheim Investigational Site

    Tel Aviv

  • 1160.71.1122 Boehringer Ingelheim Investigational Site

    Tel Aviv

Other trials in Israel

Belgium17 sites

  • 1160.71.0564 Boehringer Ingelheim Investigational Site

    Aalst

  • 1160.71.0572 Boehringer Ingelheim Investigational Site

    Brasschaat

  • 1160.71.0571 Boehringer Ingelheim Investigational Site

    Brussels

  • 1160.71.0581 Boehringer Ingelheim Investigational Site

    Brussels

  • 1160.71.0585 Boehringer Ingelheim Investigational Site

    Brussels

  • 1160.71.0563 Boehringer Ingelheim Investigational Site

    Edegem

  • 1160.71.0578 Boehringer Ingelheim Investigational Site

    Genk

  • 1160.71.0587 Boehringer Ingelheim Investigational Site

    Genk

  • 1160.71.0574 Boehringer Ingelheim Investigational Site

    Ghent

  • 1160.71.0588 Boehringer Ingelheim Investigational Site

    Gilly

  • 1160.71.0568 Boehringer Ingelheim Investigational Site

    Hasselt

  • 1160.71.0561 Boehringer Ingelheim Investigational Site

    Leuven

  • 1160.71.0579 Boehringer Ingelheim Investigational Site

    Liège

  • 1160.71.0567 Boehringer Ingelheim Investigational Site

    Ostend

  • 1160.71.0570 Boehringer Ingelheim Investigational Site

    Roeselare

  • 1160.71.0566 Boehringer Ingelheim Investigational Site

    Tienen

  • 1160.71.0562 Boehringer Ingelheim Investigational Site

    Turnhout

Other trials in Belgium

Germany17 sites

  • 1160.71.0932 Boehringer Ingelheim Investigational Site

    Berlin

  • 1160.71.0948 Boehringer Ingelheim Investigational Site

    Berlin

  • 1160.71.0962 Boehringer Ingelheim Investigational Site

    Berlin

  • 1160.71.0940 Boehringer Ingelheim Investigational Site

    Bochum

  • 1160.71.0963 Boehringer Ingelheim Investigational Site

    Cologne

  • 1160.71.0972 Boehringer Ingelheim Investigational Site

    Dortmund

  • 1160.71.0934 Boehringer Ingelheim Investigational Site

    Essen

  • 1160.71.0931 Boehringer Ingelheim Investigational Site

    Frankfurt am Main

  • 1160.71.0943 Boehringer Ingelheim Investigational Site

    Heidelberg

  • 1160.71.0946 Boehringer Ingelheim Investigational Site

    Lahr

  • 1160.71.0944 Boehringer Ingelheim Investigational Site

    Limburg

  • 1160.71.0951 Boehringer Ingelheim Investigational Site

    Mainz

  • 1160.71.0933 Boehringer Ingelheim Investigational Site

    Mannheim

  • 1160.71.0945 Boehringer Ingelheim Investigational Site

    Mannheim

  • 1160.71.0970 Boehringer Ingelheim Investigational Site

    Mannheim

  • 1160.71.0937 Boehringer Ingelheim Investigational Site

    Witten

  • 1160.71.0966 Boehringer Ingelheim Investigational Site

    Wuppertal

Other trials in Germany

India13 sites

  • 1160.71.1057 Boehringer Ingelheim Investigational Site

    Ahmedabad

  • 1160.71.1056 Boehringer Ingelheim Investigational Site

    Ahmedabad-52

  • 1160.71.1065 Boehringer Ingelheim Investigational Site

    Bangalore

  • 1160.71.1062 Boehringer Ingelheim Investigational Site

    Hyderabad

  • 1160.71.1073 Boehringer Ingelheim Investigational Site

    Jaipur, Rajasthan

  • 1160.71.1067 Boehringer Ingelheim Investigational Site

    Kerala

  • 1160.71.1068 Boehringer Ingelheim Investigational Site

    Kottayam

  • 1160.71.1055 Boehringer Ingelheim Investigational Site

    Lucknow, Uttar Pradesh

  • 1160.71.1051 Boehringer Ingelheim Investigational Site

    Ludhiana

  • 1160.71.1072 Boehringer Ingelheim Investigational Site

    Mysore

  • 1160.71.1059 Boehringer Ingelheim Investigational Site

    Nagpur-12

  • 1160.71.1052 Boehringer Ingelheim Investigational Site

    New Delhi

  • 1160.71.1070 Boehringer Ingelheim Investigational Site

    Pune, Maharashtra

Other trials in India

Taiwan13 sites

  • 1160.71.1680 Boehringer Ingelheim Investigational Site

    Changhua

  • 1160.71.1683 Boehringer Ingelheim Investigational Site

    Hualien City

  • 1160.71.1682 Boehringer Ingelheim Investigational Site

    Kaohsiung City

  • 1160.71.1679 Boehringer Ingelheim Investigational Site

    Taichung

  • 1160.71.1681 Boehringer Ingelheim Investigational Site

    Tainan

  • 1160.71.1671 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1672 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1673 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1674 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1675 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1676 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1677 Boehringer Ingelheim Investigational Site

    Taipei

  • 1160.71.1678 Boehringer Ingelheim Investigational Site

    Taoyuan

Other trials in Taiwan

Russia12 sites

  • 1160.71.1501 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1503 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1504 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1505 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1507 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1508 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1509 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1510 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1511 Boehringer Ingelheim Investigational Site

    Moscow

  • 1160.71.1512 Boehringer Ingelheim Investigational Site

    Saint Petersburg

  • 1160.71.1513 Boehringer Ingelheim Investigational Site

    Saint Petersburg

  • 1160.71.1514 Boehringer Ingelheim Investigational Site

    Saint Petersburg

Other trials in Russia

China11 sites

  • 1160.71.0771 Boehringer Ingelheim Investigational Site

    Beijing

  • 1160.71.0772 Boehringer Ingelheim Investigational Site

    Beijing

  • 1160.71.0773 Boehringer Ingelheim Investigational Site

    Beijing

  • 1160.71.0774 Boehringer Ingelheim Investigational Site

    Beijing

  • 1160.71.0776 Boehringer Ingelheim Investigational Site

    Haerbin

  • 1160.71.0784 Boehringer Ingelheim Investigational Site

    Hangzhou

  • 1160.71.0778 Boehringer Ingelheim Investigational Site

    Qingdao

  • 1160.71.0781 Boehringer Ingelheim Investigational Site

    Shanghai

  • 1160.71.0782 Boehringer Ingelheim Investigational Site

    Shanghai

  • 1160.71.0777 Boehringer Ingelheim Investigational Site

    Shenyang

  • 1160.71.0780 Boehringer Ingelheim Investigational Site

    Shijiazhuang

Other trials in China

Denmark11 sites

  • 1160.71.0837 Boehringer Ingelheim Investigational Site

    Aalborg

  • 1160.71.0835 Boehringer Ingelheim Investigational Site

    Aarhus C

  • 1160.71.0833 Boehringer Ingelheim Investigational Site

    Elsinore

  • 1160.71.0838 Boehringer Ingelheim Investigational Site

    Frederikssund

  • 1160.71.0834 Boehringer Ingelheim Investigational Site

    Herlev

  • 1160.71.0841 Boehringer Ingelheim Investigational Site

    Horsens

  • 1160.71.0832 Boehringer Ingelheim Investigational Site

    Hvidovre

  • 1160.71.0840 Boehringer Ingelheim Investigational Site

    Køge

  • 1160.71.0831 Boehringer Ingelheim Investigational Site

    Odense

  • 1160.71.0839 Boehringer Ingelheim Investigational Site

    Roskilde

  • 1160.71.0836 Boehringer Ingelheim Investigational Site

    Svendborg

Other trials in Denmark

South Korea11 sites

  • 1160.71.1585 Boehringer Ingelheim Investigational Site

    Busan

  • 1160.71.1586 Boehringer Ingelheim Investigational Site

    Cheonan-si

  • 1160.71.1584 Boehringer Ingelheim Investigational Site

    Daegu

  • 1160.71.1591 Boehringer Ingelheim Investigational Site

    Daegu

  • 1160.71.1590 Boehringer Ingelheim Investigational Site

    Gwangju

  • 1160.71.1581 Boehringer Ingelheim Investigational Site

    Incheon

  • 1160.71.1582 Boehringer Ingelheim Investigational Site

    Seoul

  • 1160.71.1583 Boehringer Ingelheim Investigational Site

    Seoul

  • 1160.71.1589 Boehringer Ingelheim Investigational Site

    Seoul

  • 1160.71.1592 Boehringer Ingelheim Investigational Site

    Seoul

  • 1160.71.1593 Boehringer Ingelheim Investigational Site

    Seoul

Other trials in South Korea

Sweden11 sites

  • 1160.71.1633 Boehringer Ingelheim Investigational Site

    Gothenburg

  • 1160.71.1627 Boehringer Ingelheim Investigational Site

    Malmö

  • 1160.71.1628 Boehringer Ingelheim Investigational Site

    Nässjö

  • 1160.71.1625 Boehringer Ingelheim Investigational Site

    Norrköping

  • 1160.71.1623 Boehringer Ingelheim Investigational Site

    Örebro

  • 1160.71.1626 Boehringer Ingelheim Investigational Site

    Stockholm

  • 1160.71.1634 Boehringer Ingelheim Investigational Site

    Stockholm

  • 1160.71.1624 Boehringer Ingelheim Investigational Site

    Umeå

  • 1160.71.1621 Boehringer Ingelheim Investigational Site

    Uppsala

  • 1160.71.1635 Boehringer Ingelheim Investigational Site

    Uppsala

  • 1160.71.1622 Boehringer Ingelheim Investigational Site

    Västerås

Other trials in Sweden

United Kingdom10 sites

  • 1160.71.1744 Boehringer Ingelheim Investigational Site

    Birmingham

  • 1160.71.1746 Boehringer Ingelheim Investigational Site

    Chertsey

  • 1160.71.1745 Boehringer Ingelheim Investigational Site

    County Armagh

  • 1160.71.1755 Boehringer Ingelheim Investigational Site

    Kirkcaldy, Fife

  • 1160.71.1741 Boehringer Ingelheim Investigational Site

    London

  • 1160.71.1742 Boehringer Ingelheim Investigational Site

    Newcastle upon Tyne

  • 1160.71.1751 Boehringer Ingelheim Investigational Site

    Newport

  • 1160.71.1752 Boehringer Ingelheim Investigational Site

    Northampton

  • 1160.71.1743 Boehringer Ingelheim Investigational Site

    Romford, Essex

  • 1160.71.1748 Boehringer Ingelheim Investigational Site

    York

Other trials in United Kingdom

Czechia9 sites

  • 1160.71.0816 Boehringer Ingelheim Investigational Site

    Modřice

  • 1160.71.0820 Boehringer Ingelheim Investigational Site

    Ostrava

  • 1160.71.0818 Boehringer Ingelheim Investigational Site

    Pardubice

  • 1160.71.0814 Boehringer Ingelheim Investigational Site

    Plzen-Bory

  • 1160.71.0811 Boehringer Ingelheim Investigational Site

    Prague

  • 1160.71.0812 Boehringer Ingelheim Investigational Site

    Prague

  • 1160.71.0813 Boehringer Ingelheim Investigational Site

    Prague

  • 1160.71.0817 Boehringer Ingelheim Investigational Site

    Příbram

  • 1160.71.0819 Boehringer Ingelheim Investigational Site

    Ústí nad Orlicí

Other trials in Czechia

Hungary9 sites

  • 1160.71.1011 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1012 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1013 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1014 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1015 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1016 Boehringer Ingelheim Investigational Site

    Budapest

  • 1160.71.1020 Boehringer Ingelheim Investigational Site

    Gyöngyös

  • 1160.71.1017 Boehringer Ingelheim Investigational Site

    Komárom

  • 1160.71.1018 Boehringer Ingelheim Investigational Site

    Pécs

Other trials in Hungary

Austria8 sites

  • 1160.71.0543 Boehringer Ingelheim Investigational Site

    Graz

  • 1160.71.0549 Boehringer Ingelheim Investigational Site

    Linz

  • 1160.71.0541 Boehringer Ingelheim Investigational Site

    Vienna

  • 1160.71.0542 Boehringer Ingelheim Investigational Site

    Vienna

  • 1160.71.0545 Boehringer Ingelheim Investigational Site

    Vienna

  • 1160.71.0547 Boehringer Ingelheim Investigational Site

    Vienna

  • 1160.71.0548 Boehringer Ingelheim Investigational Site

    Vienna

  • 1160.71.0550 Boehringer Ingelheim Investigational Site

    Wiener Neustadt

Other trials in Austria

Australia7 sites

  • 1160.71.0509 Boehringer Ingelheim Investigational Site

    Ashford, South Australia

  • 1160.71.0504 Boehringer Ingelheim Investigational Site

    Box Hill, Victoria

  • 1160.71.0508 Boehringer Ingelheim Investigational Site

    Coffs Harbour, New South Wales

  • 1160.71.0501 Boehringer Ingelheim Investigational Site

    Geelong, Victoria

  • 1160.71.0510 Boehringer Ingelheim Investigational Site

    Gosford, New South Wales

  • 1160.71.0507 Boehringer Ingelheim Investigational Site

    Launceston, Tasmania

  • 1160.71.0506 Boehringer Ingelheim Investigational Site

    Milton, Queensland

Other trials in Australia

Brazil7 sites

  • 1160.71.0644 Boehringer Ingelheim Investigational Site

    Campinas

  • 1160.71.0650 Boehringer Ingelheim Investigational Site

    Curitiba

  • 1160.71.0651 Boehringer Ingelheim Investigational Site

    Curitiba

  • 1160.71.0652 Boehringer Ingelheim Investigational Site

    Goiânia

  • 1160.71.0646 Boehringer Ingelheim Investigational Site

    Sao Jose Do Riio Preto

  • 1160.71.0647 Boehringer Ingelheim Investigational Site

    São José do Rio Preto

  • 1160.71.0643 Boehringer Ingelheim Investigational Site

    São Paulo

Other trials in Brazil

Bulgaria7 sites

  • 1160.71.0620 Boehringer Ingelheim Investigational Site

    Pleven

  • 1160.71.0611 Boehringer Ingelheim Investigational Site

    Sofia

  • 1160.71.0612 Boehringer Ingelheim Investigational Site

    Sofia

  • 1160.71.0615 Boehringer Ingelheim Investigational Site

    Sofia

  • 1160.71.0617 Boehringer Ingelheim Investigational Site

    Sofia

  • 1160.71.0618 Boehringer Ingelheim Investigational Site

    Sofia

  • 1160.71.0625 Boehringer Ingelheim Investigational Site

    Sofia

Other trials in Bulgaria

Poland7 sites

  • 1160.71.1436 Boehringer Ingelheim Investigational Site

    Gdynia

  • 1160.71.1437 Boehringer Ingelheim Investigational Site

    Gdynia

  • 1160.71.1438 Boehringer Ingelheim Investigational Site

    Gdynia

  • 1160.71.1433 Boehringer Ingelheim Investigational Site

    Puławy

  • 1160.71.1431 Boehringer Ingelheim Investigational Site

    Warsaw

  • 1160.71.1432 Boehringer Ingelheim Investigational Site

    Warsaw

  • 1160.71.1434 Boehringer Ingelheim Investigational Site

    Zabrze

Other trials in Poland

Finland6 sites

  • 1160.71.0851 Boehringer Ingelheim Investigational Site

    Helsinki

  • 1160.71.0859 Boehringer Ingelheim Investigational Site

    Jyväskylä

  • 1160.71.0854 Boehringer Ingelheim Investigational Site

    Oulu

  • 1160.71.0858 Boehringer Ingelheim Investigational Site

    Pori

  • 1160.71.0852 Boehringer Ingelheim Investigational Site

    Tampere

  • 1160.71.0853 Boehringer Ingelheim Investigational Site

    Turku

Other trials in Finland

Greece6 sites

  • 1160.71.0901 Boehringer Ingelheim Investigational Site

    Athens

  • 1160.71.0914 Boehringer Ingelheim Investigational Site

    Kalamaria-Thessaloniki

  • 1160.71.0904 Boehringer Ingelheim Investigational Site

    Larissa

  • 1160.71.0910 Boehringer Ingelheim Investigational Site

    Thebes

  • 1160.71.0903 Boehringer Ingelheim Investigational Site

    Trikala

  • 1160.71.0905 Boehringer Ingelheim Investigational Site

    Voula - Athens

Other trials in Greece

Norway6 sites

  • 1160.71.1396 Boehringer Ingelheim Investigational Site

    Gjøvik

  • 1160.71.1393 Boehringer Ingelheim Investigational Site

    Moss

  • 1160.71.1395 Boehringer Ingelheim Investigational Site

    Nordbyhagen

  • 1160.71.1391 Boehringer Ingelheim Investigational Site

    Oslo

  • 1160.71.1397 Boehringer Ingelheim Investigational Site

    Oslo

  • 1160.71.1394 Boehringer Ingelheim Investigational Site

    Rud

Other trials in Norway

Portugal6 sites

  • 1160.71.1456 Boehringer Ingelheim Investigational Site

    Amadora

  • 1160.71.1451 Boehringer Ingelheim Investigational Site

    Carnaxide

  • 1160.71.1454 Boehringer Ingelheim Investigational Site

    Coimbra

  • 1160.71.1459 Boehringer Ingelheim Investigational Site

    Coimbra

  • 1160.71.1457 Boehringer Ingelheim Investigational Site

    Covilha

  • 1160.71.1455 Boehringer Ingelheim Investigational Site

    Porto

Other trials in Portugal

Slovakia6 sites

  • 1160.71.1548 Boehringer Ingelheim Investigational Site

    Banská Bystrica

  • 1160.71.1541 Boehringer Ingelheim Investigational Site

    Bratislava

  • 1160.71.1542 Boehringer Ingelheim Investigational Site

    Bratislava

  • 1160.71.1543 Boehringer Ingelheim Investigational Site

    Bratislava

  • 1160.71.1550 Boehringer Ingelheim Investigational Site

    Košice

  • 1160.71.1547 Boehringer Ingelheim Investigational Site

    Žilina

Other trials in Slovakia

Philippines5 sites

  • 1160.71.1422 Boehringer Ingelheim Investigational Site

    Ermita Manila

  • 1160.71.1421 Boehringer Ingelheim Investigational Site

    Manila

  • 1160.71.1424 Boehringer Ingelheim Investigational Site

    Pasig

  • 1160.71.1423 Boehringer Ingelheim Investigational Site

    Quezon City

  • 1160.71.1425 Boehringer Ingelheim Investigational Site

    Quezon City

Other trials in Philippines

Switzerland4 sites

  • 1160.71.1652 Boehringer Ingelheim Investigational Site

    Basel

  • 1160.71.1655 Boehringer Ingelheim Investigational Site

    Bellinzona

  • 1160.71.1651 Boehringer Ingelheim Investigational Site

    Bern

  • 1160.71.1654 Boehringer Ingelheim Investigational Site

    Lugano

Other trials in Switzerland

Italy3 sites

  • 1160.71.1169 Boehringer Ingelheim Investigational Site

    Arezzo

  • 1160.71.1172 Boehringer Ingelheim Investigational Site

    Ascoli Piceno

  • 1160.71.1170 Boehringer Ingelheim Investigational Site

    Sassari

Other trials in Italy

Thailand3 sites

  • 1160.71.1701 Boehringer Ingelheim Investigational Site

    Bangkok

  • 1160.71.1703 Boehringer Ingelheim Investigational Site

    Chiang Mai

  • 1160.71.1704 Boehringer Ingelheim Investigational Site

    Khon Kaen

Other trials in Thailand

Hong Kong2 sites

  • 1160.71.1003 Boehringer Ingelheim Investigational Site

    Kowloon

  • 1160.71.1004 Boehringer Ingelheim Investigational Site

    Kowloon

Other trials in Hong Kong

Malaysia2 sites

  • 1160.71.1291 Boehringer Ingelheim Investigational Site

    Kuala Lumpur

  • 1160.71.1292 Boehringer Ingelheim Investigational Site

    Kuala Lumpur

Other trials in Malaysia

Romania2 sites

  • 1160.71.1471 Boehringer Ingelheim Investigational Site

    Bucharest

  • 1160.71.1472 Boehringer Ingelheim Investigational Site

    Bucharest

Other trials in Romania

Singapore1 site

  • 1160.71.1531 Boehringer Ingelheim Investigational Site

    Singapore

Other trials in Singapore

About this study

Official title: RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

The purposes of this study are:

  1. To evaluate the long-term safety of dabigatran etexilate
  2. To assess the effect of a knowledge translation intervention on patient outcomes
Being tested
dabigatran dose 1, dabigatran dose 2
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dabigatran dose 1Drug

    dabigatran high dose twice daily

  • dabigatran dose 2Drug

    dabigatran low dose twice daily

Study groups in NCT00808067
Study groupRoleWhat they receive
dabigatran dose 1Experimentaldabigatran high dose twice daily
Receives: Drug: dabigatran dose 1
dabigatran dose 2Experimentaldabigatran low dose twice daily
Receives: Drug: dabigatran dose 2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major Bleeding, Annualized Rate of Subjects With Major Bleeds

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Major bleeding must have satisfied one or more of the following criteria:

    • Bleeding associated with a reduction in hemoglobin of at least 20 g/L
    • Required transfusion of at least 2 units of blood or packed cells
    • Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal

    Major bleed were classified as life-threatening if they met one or more of the following criteria:

    • Reduction in hemoglobin of at least 50 g/L
    • Transfusion of at least 4 units of blood or packed cells
    • Symptomatic intracranial bleeding, either subdural or intracerebral
    • Associated with hypotension requiring use of intravenous inotropic agents
    • Required surgical intervention to stop bleeding
    • Resulted in death

    Measured: up to 43 months

Secondary outcomes (13)

  1. Stroke, Annualized Rate of Subjects With Stroke

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital

    Measured: up to 43 months

  2. Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy.

    Measured: up to 43 months

  3. Pulmonary Embolism (PE), Annualized Rate of Subjects With PE

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Pulmonary Embolism was generally documented by one of the following:

    1. an intraluminal filling defect in segmental or more proximal branches on spiral CT scan
    2. an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram
    3. a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)
    4. inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography.

    Measured: up to 43 months

  4. Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    1. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy.

    Measured: up to 43 months

  5. Deep Vein Thrombosis, Annualized Rate of Subjects With DVT

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Deep Vein Thrombosis (DVT) was generally documented by one of the following:

    1. abnormal compression ultrasound (CUS),
    2. an intraluminal filling defect on venography.

    Measured: up to 43 months

  6. Death, Annualized Rate of Subject Death

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology.

    Measured: up to 43 months

  7. Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

  8. Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

  9. Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

  10. Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

  11. Annualized Rate of Subjects With Minor Bleeds

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not.

    Measured: up to 43 months

  12. Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

  13. Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)

    Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

    Measured: up to 43 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2008 (estimated)
  2. Study startNov 2008
  3. Primary completionDec 2012
  4. Study completionDec 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
5,897 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00808067
Sponsor's protocol ID
1160.71
Other IDs
2008-005248-17, 2008
Status last verified
Mar 2014
First submitted
12 Dec 2008
Last updated
9 Jun 2014

Publications

  • Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.

    PubMed 23770747

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing dabigatran dose 1 and dabigatran dose 2 in people with Atrial Fibrillation, run by Boehringer Ingelheim at 567 sites in 35 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 567 sites in United States, Canada, Netherlands, France, Israel and 30 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major Bleeding, Annualized Rate of Subjects With Major Bleeds (time frame: up to 43 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00808067, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2014.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in